The industry needs to bring safer biologics to patient in a more ethical and time effective. Classical viral safety testing approaches often fail to keep pace with the demands faced with new and innovative biomedicines and they have fallen out of favor considering the 3Rs (replacement, reduction, refinement of animal testing). See the calendar in regards with the presentation of the new comparison study between NGS and in vivo.
VIRAL SAFETY BY DESIGN FOR CELL AND GENE THERAPY PRODUCTS Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologics. Adventitious agents (viruses, bacteria, mycoplasma,…
Watch the replay of our webinar – Accelerated vaccines development and production: in-process NGS QC testing for risk mitigations
Archived version of our webinar: Accelerated vaccines development and production: in-process NGS QC testing for risk mitigations Appropriate safety testing is an important part of vaccine development and production.
Watch the replay of our webinar – The Benefits of NGS-Based Quality Control for Routine Biologics testing using GLP-Certified Solutions
PathoQuest is offering a GLP-certified (grade A) NGS solutions further to the successful inspection of ANSM in December 2019. Watch why NGS is a fast and reliable quality control test for adventitious agents’ detection and viral stock characterization that supplement and replace sub-optimal traditional methods, in particular for ATMPs’ testing.
Learn more about the use of high-throughput sequencing (HTS) to identify viral contamination of biological products with a new approach to differentiate inert versus active viral sequences to assist customers with de-risking the production process.